Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1.-22. (Canceled)

23. (Currently amended) A compound of the following formula:



wherein:

A is thienyl, optionally substituted **with from one to two halogen atoms**;

W is phenylene, optionally substituted **with from one to two substituents selected from the group consisting of halogen, methyl and trifluoromethyl**;

E is selected from the group consisting of H, -C_1-C_8 alkyl, polyhaloalkyl~~,~~ **and** -C_{3-8}-cycloalkyl~~, aryl, alkylaryl, substituted aryl, heteroaryl, and substituted heteroaryl~~;

n is an integer from 0-4;

each instance of X^1, X^2 and X^3 is a member independently selected from the group consisting of hydrogen, halogen, polyhaloalkyl, -OR^3, -SR^3, -CN, -NO_2, -SO_2R^3, **-$CONHR^3$, -$C(=NH)NHCH_3$,** -C_{1-10}-alkyl, -C_{3-8}-cycloalkyl, aryl, aryl-substituted by 1-4 R^3 groups, amino, amino-C_{1-8}-alkyl, C_{1-3}-acylamino, C_{1-3}-acylamino-C_{1-8}-alkyl, C_{1-6}-alkylamino, C_{1-6}-alkylamino C_{1-8} alkyl, C_{1-6} dialkylamino, C_{1-6} dialkylamino C_{1-8} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxy-C_{1-6}-alkyl, carboxy-C_{1-6}-alkyl, C_{1-3}-alkoxycarbonyl, C_{1-3}-alkoxycarbonyl- C_{1-6}-alkyl, carboxy C_{1-6} alkyloxy, hydroxy, hydroxy C_{1-6} alkyl, ~~and~~ a 5 ~~to 10~~ membered fused **pyrrolidino, imidazolo, thiazolo or oxazolo** ~~or non-fused aromatic or nonaromatic heterocyclic~~ ring ~~system, having 1 to 4 heteroatoms independently selected from N, O, and S,~~ **and a 5 to 6 membered aromatic or nonaromatic heterocyclic ring selected from the group consisting of oxazolinyl, pyrrolidinyl, imidazolinyl and pyridyl,** with the proviso that the carbon and

nitrogen atoms, when present in the heterocyclic ring ~~system~~, are unsubstituted, mono- or di-substituted independently with 0-2 R^4 groups;

R^3 and R^4 are each independently selected from the group consisting of hydrogen, halogen, -CN, $-NO_2$, $-C_{1-10}$ alkyl, C_{3-8}-cycloalkyl, aryl, amino, amino-C_{1-8}-alkyl, C_{1-3}-acylamino, C_{1-3}-acylamino-C_{1-8}-alkyl, C_{1-6}-alkylamino, C_{1-6}-alkylamino C_{1-8} alkyl, C_{1-6} dialkylamino, C_{1-6} dialkylamino C_{1-8} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxy-C_{1-6}-alkyl, carboxy-C_{1-6}-alkyl, C_{1-3}-alkoxycarbonyl, C_{1-3}-alkoxycarbonyl-C_{1-6}-alkyl, carboxy-C_{1-6}-alkyloxy, hydroxy, hydroxy-C_{1-6}-alkyl, -thio and thio-C_{1-6}-alkyl**, wherein optionally two alkyl groups attached to a nitrogen atom can be combined with the nitrogen atom to form a pyrrolidinyl, piperidinyl or morpholinyl ring**;

Y is selected from the group consisting of O, S, N-OR^5 and NR^5;

R^5 is selected from the group consisting of H, C_{1-10} alkyl, C_{3-8}-cycloalkyl, and CN;

or pharmaceutically acceptable salts ~~and prodrugs~~.

24. (Original) A compound according to claim 23, wherein

A is selected from the group consisting of:



;

Y is selected from the group consisting of O, S, N-OR^5 and NR^5;

E is selected from the group consisting of H, or C_{1-8}alkyl; and

W is selected from the group consisting of:



25. (Currently amended) A compound of claim 23, selected from the group consisting of:



Example 56



Example 57



Example 58



Example 59



Example 60



Example 61



Example 62



Example 63



Example 64



Example 65



Example 66



Example 67



Example 68



Example 69



Example 70



Example 71



Example 72



Example 73



Example 74



Example 110



Example 111



Example 112



Example 113



Example 114



Example 115



Example 116



Example 117



Example 118



Example 119



Example 120



Example 121



Example 122



Example 123



Example 124



Example 125



Example 214



Example 215



Example 216



Example 217



Example 218



Example 219



Exampl 220



exampl 221



Example 222



Example 223



Example 224



Example 225



Example 226



Example 227



Example 228



Exampl 229



Example 230



Example 231



Example 232



Example 370



Example 371



Example 372



Example 373



Example 374



Example 375



Example 376



Example 377



Exampl 378



Exampl 379



Example 380



Example 381



Example 382



Example 383



Example 384



Example 385



Example 386



Example 387



~~Example 388~~



Example 389



Example 390



Example 391



Example 392



Example 393



Example 394



Exampl 395



Exampl 396



Example 397



Example 398



Example 399



Example 400



Example 401



Example 402



Example 403



Example 404



Example 405



Example 406



Example 407



Example 408



Example 409



Example 410



Example 411



Example 412



Exampl 413



Example 414



Example 415



Example 416



Example 417



Example 418



Example 419



Example 420



Example 421



~~Example 422~~



Example 423



Example 424



Example 425



Example 426



Example 427



Example 428



Example 429



Example 430



Example 431



Example 432



Example 433



Example 434



Example 435



Example 436



Example 437



Example 472



Example 473



Example 474



Example 475



Example 476



Example 477



Example 478



Example 479



Example 480



Example 481



Example 482



Example 483



Example 484



Example 485



Example 486



Example 487



Example 488



Example 489



~~Example 490~~



Example 491



Example 492



Example 493



Example 494



Example 495



Example 496



Exampl 497



Exampl 498



Example 499



Example 500



Example 501



Example 502



Example 503



Example 504



Example 505



Example 769



Example 770



Example 781



Example 782



Example 783



Example 784



Example 785



Example 786



Example 787



Example 788



Example 789



Example 790



Example 791



Example 792



Example 793



Example 794



Example 795



Example 796



Example 797



Example 833



Example 834



Example 835



Example 836



Example 837



Example 838



Example 839



Example 840



Example 841



Example 842



Example 843



Example 844



Example 845



Example 846



Example 847



Example 848



Example 933



Example 934



Example 936



and

Example 937



Example 938

26. (Currently amended) A pharmaceutical composition ~~for treating thrombosis in a mammal~~ comprising a therapeutically effective amount of a compound according to claim 23, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

27. (Canceled) A pharmaceutical composition of claim 26, wherein said therapeutically effective amount is an amount effective to inhibit platelet aggregation in the mammal.

28. (Canceled) A pharmaceutical composition of claim 27, wherein said platelet aggregation is ADP-dependent aggregation.

29. (Canceled) A pharmaceutical composition of claims 26 and 28, wherein said mammal is a human.

30. (Canceled) A pharmaceutical composition of claim 26, wherein said compound is an effective inhibitor of [^{3}H]2-MeS-ADP binding to platelet ADP receptors.

31. (Currently amended) A pharmaceutical composition ~~for treating thrombosis in a mammal~~ comprising a therapeutically effective amount of a compound according to claims 24-25, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

32. (Canceled) A pharmaceutical composition of claim 31, wherein said therapeutically effective amount is an amount effective to inhibit platelet aggregation in the mammal.

33. (Canceled) A pharmaceutical composition of claim 32, wherein said platelet aggregation is ADP-dependent aggregation.

34. (Canceled) A pharmaceutical composition of claims 30 and 33, wherein said mammal is a human.

35. (Canceled) A pharmaceutical composition of claim 31, wherein said compound is an effective inhibitor of [^{3}H]2-MeS-ADP binding to platelet ADP receptors.

36. (Original) A method for treating thrombosis in a mammal comprising the step of administering to a mammal a therapeutically effective amount of a compound of claim 23 or a pharmaceutically acceptable salt thereof.

37. (Original) A method of claim 36, wherein said mammal is a human.

38. (Original) A method of claim 36, wherein said thrombosis is indicated by at least one selected from the group consisting of acute myocardial infarction, unstable angina, chronic stable angina, transient ischemic attacks, strokes, peripheral vascular disease, preeclampsia/eclampsia, deep venous thrombosis, embolism, disseminated intravascular coagulation and thrombotic cytopenic purpura, thrombotic and restenotic complications following invasive procedures resulting from angioplasty, carotid endarterectomy, post CABG (coronary artery bypass graft) surgery, vascular graft surgery, stent placements and insertion of endovascular devices and protheses.